5/25/2017 CRITICAL ROLE OF THE PATHOLOGIST IN THE BLADDER CANCER - - PowerPoint PPT Presentation

▶
5 25 2017
SMART_READER_LITE
LIVE PREVIEW

5/25/2017 CRITICAL ROLE OF THE PATHOLOGIST IN THE BLADDER CANCER - - PowerPoint PPT Presentation

Feb 01, 2023 288 likes •568 views

5/25/2017 CRITICAL ROLE OF THE PATHOLOGIST IN THE BLADDER CANCER EPIDEMIOLOGY (2014) MANAGEMENT OF BLADDER CANCER Urinary bladder 18,300 2.3% Urinary bladder 4,410 1.6% Southern

slide-1
SLIDE 1

5/25/2017 1

“Southern Alps” South Island, NZ

CRITICAL ROLE OF THE PATHOLOGIST IN THE MANAGEMENT OF BLADDER CANCER

BLADDER CANCER EPIDEMIOLOGY (2014)

Siegel et al. CaA Cancer J Clin 64:9-29, 2014

Urinary bladder 18,300 2.3% Urinary bladder 4,410 1.6%

slide-2
SLIDE 2

5/25/2017 2 EORTC RISK TABLES Patients presenting with Ta/Tis/T1 tumors

RECURRENCE

  • 6 - Number of tumors
  • 4 - Prior recurrence
  • 3 - Tumor size
  • 2 - Grade
  • 1 - T-category
  • 1 - CIS

PROGRESSION*

  • 6 - CIS
  • 5 - Grade
  • 4 - T-category
  • 3 - Number of tumors
  • 3 - Tumor size
  • 2 - Prior recurrence

Sylvester et al. Eur Urol 49:466, 2006 *Progression = development of muscle invasive disease

WHO/ISUP 2004/2016 CLASSIFICATION

  • NORMAL
  • FLAT LESIONS WITH ATYPIA

– Reactive (inflammatory) atypia – Atypia of unknown significance – Dysplasia (low grade intraurothelial neoplasia) – Carcinoma in situ (high grade intraurothelial neoplasia)

  • PAPILLARY NEOPLASMS

– Papilloma – Inverted papilloma – Papillary neoplasm of low malignant potential – Papillary carcinoma, low grade – Papillary carcinoma, high grade

  • INVASIVE NEOPLASMS

NORMAL UROTHELIUM

Cytokeratin 20

slide-3
SLIDE 3

5/25/2017 3

REACTIVE ATYPIA REACTIVE ATYPIA DYSPLASIA DYSPLASIA

slide-4
SLIDE 4

5/25/2017 4

DYSPLASIA

Or Incipient Papillary Neoplasia?

CIS “flat urothelial lesion…containing cytologically malignant cells”

Cytokeratin 20

CIS - LARGE CELL CIS - LARGE CELL

slide-5
SLIDE 5

5/25/2017 5

CARCINOMA IN SITU

Abundant eosinophilic cytoplasm

CIS – “SMALL CELL” CIS - DENUDING

CIS – DENUDING – VON BRUNN’S NESTS

slide-6
SLIDE 6

5/25/2017 6

CARCINOMA IN SITU

No surface epithelium

CARCINOMA IN SITU

Pagetoid growth

SV: CIS - PAGETOID

CARCINOMA IN SITU

Early invasion

slide-7
SLIDE 7

5/25/2017 7

CARCINOMA IN SITU – p53 IHC

~ 80% Positive

CARCINOMA IN SITU

CK20

CARCINOMA IN SITU

CK20 P53

CARCINOMA IN SITU

AMACR

CK 20

slide-8
SLIDE 8

5/25/2017 8 REACTIVE ATYPIA

CK20 p53

UROTHELIAL CARCINOMA IN SITU - LONG TERM OUTCOME

SURVIVAL-TYPE 10-Year 15-Year Progression-free 63% 59% Cancer-specific 79% 74% All-cause 55% 40%

Cheng et al, Cancer 85:2469, 2000

CLASSIFICATION AND GRADING OF PAPILLARY UROTHELIAL NEOPLASMS

BASED ON TWO KEY FEATURES

  • Architectural disruption
  • Degree of cytologic atypia

UROTHELIAL PAPILLOMA

  • Most are small
  • Essentially normal

urothelium

  • Often vacuolated

umbrella cells

slide-9
SLIDE 9

5/25/2017 9

PAPILLOMA

PAPILLARY UROTHELIAL NEOPLASM OF LOW MALIGNANT POTENTIAL

PUNLMP

PUNLMP LOW GRADE

slide-10
SLIDE 10

5/25/2017 10

LOW GRADE

LOW GRADE

HIGH GRADE HIGH GRADE

HIGH GRADE

slide-11
SLIDE 11

5/25/2017 11 HIGH GRADE PAPILLARY

BLADDER – PAPILLARY UC

52/164 (32%) papillary UC were grade heterogeneous Cheng et al. Cancer 88:1663-1670, 2000

EARLY PAPILLARY CARCINOMA

WHO 1973 vs WHO 2016

Papilloma Papilloma Papillary urothelial neoplasm of low malignant potential Papillary ca, low grade Papillary ca, high grade Papillary ca, I Papillary ca, II Papillary ca, III

slide-12
SLIDE 12

5/25/2017 12

pTa BLADDER CA LONG TERM OUTCOME

Pan et al, AJCP 133:788, 2010

N=175 N=483 N=129

Progression in stage

pTa BLADDER CA LONG TERM OUTCOME

Pan et al, AJCP 133:788, 2010 Cancer-specific mortality

N=175 N=483 N=129

Hobbiton as seen from the Green Dragon

STAGING OF BLADDER CANCER (2010 TNM)

  • pTa

Non-invasive, papillary

  • pTis

Non-invasive, flat

  • pT1

Invasion of subepithelial connective tissue (lamina propria)

  • pT2

Invasion of muscularis propria

– pT2a inner one-half – pT2b outer one-half

  • pT3

Invasion of perivesical tissue

– pT3a microscopically – pT3b macroscopically

  • pT4

Invasion of adjacent structures

slide-13
SLIDE 13

5/25/2017 13 BLADDER CANCER: OUTCOME AFTER CYSTECTOMY

N=1,100

Hautmann et al. Eur Urol 61:1039, 2012

TREATMENT OF T1 DISEASE

“ On the basis of clinical and administrative data, we estimate that between 31.2% and 46.8% of deaths potentially were avoidable.”

Cancer 115:1011, 2009

TREATMENT OF T1 DISEASE

2008;102:270-275

15% 83%

Eur Urol 57:60-70, 2010

slide-14
SLIDE 14

5/25/2017 14

TREATMENT OF T1 DISEASE

2008;102:270-275

RADICAL CYSTECTOMY FOR NON-MUSCLE INVASIVE BLADDER CANCER:

EAU GUIDELINES 2016 UPDATE “RC should be considered:”

  • Multiple and/or large (> 3cm) T1, HG/G3

tumors

  • T1, HG/G3 tumors with concurrent CIS
  • Recurrent T1, HG/G3 tumors
  • T1, HG/G3 tumors with CIS in prostatic

urethra

  • Unusual histology of urothelial carcinoma
  • Lymphvascular invasion present

Babjuk et al. Eur Urol 71:447-461, 2017

DIAGNOSIS OF INVASION

Irregular nests Stromal response

DIAGNOSIS OF INVASION

Increased cytoplasm Retraction artifact

slide-15
SLIDE 15

5/25/2017 15

DIAGNOSIS OF INVASION

Increased cytoplasm Retraction artifact

DIAGNOSIS OF INVASION

T1 SUBSTAGING

Cheng et al. J Clin Oncol 17:3182, 1999

pT1m: a single microscopic focus ≤

  • ne HPF

pT1e: a single microscopic focus >

  • ne HPF or more than one focus

van Rhijn et al. Eur Urol 61:378, 2012

T1 SUBSTAGING

Chang et al. Am J Surg Pathol 36:454, 2012

N=1,515

HGPUC Ta vs T1 ≤ 1mm HGPUC T1 ≤ 1mm vs > 1mm

slide-16
SLIDE 16

5/25/2017 16

T1 SUBSTAGING

(≤ 1 HPF vs > 1 HPF)

Bertz et al. Histopathology 59:722, 2011.

P<0.001 P=0.012 N=301 N=301

Progression-free survival Cancer-specific survival

MUSCULARIS MUCOSAE MUSCULARIS MUCOSAE TRIGONE REGION

slide-17
SLIDE 17

5/25/2017 17

TRIGONE REGION

MUSCULARIS MUCOSAE INVASION MUSCULARIS MUCOSAE INVASION

MUSCULARIS PROPRIA INVASION

slide-18
SLIDE 18

5/25/2017 18 MM vs MP INVASION

pT1 – SUBSTAGING: MUSCULARIS MUCOSAE

“pT1a” “pT1b”

SURVIVAL ACCORDING TO MUSCULARIS MUCOSAE INVASION

  • 343 patients -

initial treatment

  • 170 pT1
  • Cases centrally

reviewed

  • Substaging

possible in 99 (58%)

  • Treated by:
  • TURBT with

intravesical tx Angulo et al, J Cancer Res Clin Oncol 119:578, 1993 P<0.02

“Based on the available data, it is recommended to provide an assessment

  • f the depth and/or extent of

subepithelial invasion inT1 cases.” Grignon et al. Infiltrating urothelial carcinoma (p97)

slide-19
SLIDE 19

5/25/2017 19 COLLEGE OF AMERICAN PATHOLOGISTS: 2017 REPORTING GUIDELINES

URINARY BLADDER (BIOPSY/TRANSURETHRAL RESECTION)

“Depth of invasion is a critical prognostic determinant in invasive urothelial carcinoma. In T1 disease, several substaging methods have been proposed but have been difficult to adopt due in part to the inherent lack of orientation of the specimen.10,13 Pathologists are, however, encouraged to provide some assessment as to the extent of lamina propria invasion (ie, maximum dimension of invasive focus, or depth in millimeters, or by level – above, at, or below muscularis mucosae).”

T1 UC WITH LYMPHVASCULAR INVASION

  • 118 newly diagnosed T1; all with TURBT +/- intra-vesical tx (85%)
  • LVI diagnosis based on H&E alone
  • LVI diagnosed in 33 cases (28%)

Cho et al. J Urol 182:2625-2631, 2009

PROBLEMS WITH IDENTIFICATION OF LYMPHVASCULAR INVASION

“The general use of immunohistochemistry in the routine setting, however, cannot be recommended” Amin et al. Pathology Consensus Guidelines, International Consultation on Urologic Diseases, 2012

GRADE AS A PREDICTOR OF OUTCOME IN pT1 CA TREATED BY TURBT

Kaubisch et al, J Urol 146:28-31, 1991

slide-20
SLIDE 20

5/25/2017 20 GRADE AS A PREDICTOR OF OUTCOME IN pT1 CA TREATED BY TURBT

Kaubisch et al, J Urol 146:28-31, 1991 “The overwhelming majority of invasive urothelial carcinomas are high grade” Grignon et al. WHO 2016, p86 UROTHELIAL CARCINOMA - PATTERN OF INVASION

Jimenez et al, Am J Surg Pathol 24:980, 2000

UROTHELIAL CARCINOMA SURVIVAL BY PATTERN OF INVASION

Jimenez et al, Am J Surg Pathol 24:980, 2000 Denzinger et al. Scand J Urol 43:282, 2009

UROTHELIAL CARCINOMA

HISTOLOGIC VARIANTS (2016)

  • Divergent differentiation

– Squamous differentiation – Glandular differentiation – Trophoblastic differentiation – Müllerian differentiation

  • Nested variant
  • Microcystic variant
  • Micropapillary variant
  • Plasmacytoid variant
  • Clear cell type
  • Lipid-rich
  • Lymphoepithelioma-like variant
  • Giant cell
  • Sarcomatoid carcinoma
slide-21
SLIDE 21

5/25/2017 21

2008;102:270-275

PROGNOSITIC SIGNIFICANCE OF VARIANT HISTOLOGY

Xylinas et al. Eur J Cancer 49:1889-1897, 2013

  • Multi-institutional (5)
  • Radical cystectomy 2000 – 2008
  • No neoadjuvant treatment

RECOGNITION OF VARIANT HISTOLOGY

VARIANT NUMBER* PERCENT PERCENT NOT RECOGNIZED Squamous differentiation 32 32% <25% Small cell differentiation 16 16% 44% Glandular differentiation 13 13% <25% Micropapillary 12 12% 83% Nested 8 8% 87% Sarcomatoid 6 6% NA Lymphoepithelioma-like 3 3% 100% Plasmacytoid 1 1% 100% Multiple types 10 10% NA * Variant histology present in 115/589 (20%) of TURBT cases reviewed (2004 – 2008)

Shah et al. Urol Oncol 31:1650, 2013

UROTHELIAL CARCINOMA MICROPAPILLARY TYPE

  • CLINICAL

– Similar epidemiology to usual TCC – High stage, 50% with + LN at diagnosis – Worse prognosis with high % MP

  • PATHOLOGY

– Small, tight clusters of cells – Open spaces simulating lymphatic invasion – Deeply invasive – Suggested to be a form of glandular differentiation – Inversion of MUC1 staining to stromal aspect

slide-22
SLIDE 22

5/25/2017 22

MICROPAPILLARY VARIANT

MICROPAPILLARY VARIANT MICROPAPILLARY VARIANT

MICROPAPILLARY VARIANT

slide-23
SLIDE 23

5/25/2017 23 UC - MICROPAPILLARY VARIANT

CD 34

UC - MICROPAPILLARY VARIANT: DIAGNOSTIC CRITERIA

  • High degree of agreement with “classical

cases” (Kappa value 0.79)

  • Less agreement for equivocal cases
  • Key features for diagnosis included:
  • Extensive retraction artifact
  • Multiple nests within the same lacunar

space

  • Epithelial ring forms
  • Peripheral nuclear orientation

Sangoi et al. Am J Surg Pathol 34:1367, 2010

UC - MICROPAPILLARY VARIANT: DIAGNOSTIC CRITERIA

UC - MICROPAPILLARY VARIANT URETER FROZEN SECTION

slide-24
SLIDE 24

5/25/2017 24 UC - MICROPAPILLARY VARIANT

Lopez-Beltran et al. Hum Pathol 42:1159-1164, 2010 Comperat et al. Pathology 42:650-654, 2010

UC – MICROPAPILLARY VARIANT: OUTCOME

N=24 N=72

UROTHELIAL CARCINOMA PLASMACYTOID CELL TYPE

  • CLINICAL

– Described by Saphir in 1955 (“monocytoid SRC”) – Highly aggressive tumor – Linitis plastica-like; often no discrete mass but edematous mucosa in many

  • PATHOLOGY

– Sheets of poorly cohesive cells – Distinct monocytoid/plasmacytoid morphology with variable numbers of true signet-ring cells – +/- typical UC component – CK ++ (variable CK7/CK20), p63+, LCA -

PLASMACYTOID CARCINOMA

slide-25
SLIDE 25

5/25/2017 25

PLASMACYTOID CARCINOMA

Plasmacytoid variant

PLASMACYTOID CARCINOMA PLASMACYTOID CARCINOMA

slide-26
SLIDE 26

5/25/2017 26 PLASMACYTOID CARCINOMA

PLASMACYTOID VARIANT

CK 7 CK 20 CD 138

PLASMACYTOID CARCINOMA

E-CADHERIN

PATTERN OF SPREAD

Rectum Lymph node Pelvic wall Fallopian Tube

slide-27
SLIDE 27

5/25/2017 27

Plasmacytoid UC – Ureter Margin Frozen Section Plasmacytoid UC – Ureter Margin Frozen Section

PLASMACYTOID CARCINOMA

Keck et al. BMC Cancer 13:71, 2013 Mirror Lake, South Island, NZ